Flea control remains an integral component of canine healthcare throughout much of Europe. The latest addi tion to the options available to veterinarians for this purpose is spinosad, a naturally occurring mixture of spinosyns A and D formed during a fermentation pro cess. Spinosyns are tetracyclic macrolides with a unique ring system. They exhibit a novel mode of action primar ily involving nicotinic acetylcholine receptor binding sites distinct from those targeted by other insecticides. Spinosad is presented for flea control as chewable tab lets (Comfortis; Elanco). Preliminary studies indicated that effective control of Ctenocephalides felis on dogs could be achieved over a fourweek period with dose rates of 30 mg spinosad/kg bodyweight or above. A minimum dose of 45 mg/kg was selected for European labora tory studies to ensure compliance with local regulatory requirements.
Context
Flea control remains an integral component of canine healthcare throughout much of Europe. The latest addi tion to the options available to veterinarians for this purpose is spinosad, a naturally occurring mixture of spinosyns A and D formed during a fermentation pro cess. Spinosyns are tetracyclic macrolides with a unique ring system. They exhibit a novel mode of action primar ily involving nicotinic acetylcholine receptor binding sites distinct from those targeted by other insecticides. Spinosad is presented for flea control as chewable tab lets (Comfortis; Elanco). Preliminary studies indicated that effective control of Ctenocephalides felis on dogs could be achieved over a fourweek period with dose rates of 30 mg spinosad/kg bodyweight or above. A minimum dose of 45 mg/kg was selected for European labora tory studies to ensure compliance with local regulatory requirements.
Main conclusion
Laboratory and field investigations in Europe confirmed that spinosad administered orally to dogs at a dose rate of 45 to 70 mg/kg is highly effective for the treatment and control of flea infestations on dogs, with activity against new infestations persisting for up to four weeks. The field performance of spinosad compared favourably with that of a reference product, selamectin (Stronghold; Pfizer).
Approach
Three laboratory and two multicentre field studies were conducted in compliance with international guidelines and ethical requirements. In laboratory studies, individu ally housed beagles were allocated to spinosadtreated or placebotreated groups, each comprising six or more dogs. Efficacy was assessed by infesting dogs at intervals with 100 C felis and counting the number of surviving fleas after 48 hours. Study 1 used unformulated spinosad powder at a dose rate of 45 mg/kg with fleas applied 21 and 28 days after dosing. Studies 2 and 3 used tablets providing 45 to 54 mg spinosad/kg, with fleas applied on the day before treat ment (study 2) and on days 7, 14, 21 and 28 (both studies). Statistical comparisons were based on geometric means to account for skewness of data.
The field trials included a onemonth study in five European countries (study 4) and a threemonth study in France (study 5). Dogs naturally infested with at least 10 fleas were randomly assigned to two groups and treated monthly. Spinosadtreated dogs were administered whole tablets according to a schedule that allowed a minimum dose of 30 mg/kg. Selamectin was applied topically as per the label instructions. Dogs in a multipet home were treated with the same product, but all cats received sela mectin (as no spinosad formulation was available for cats). The experimental unit was the household represented by one designated dog. A standardised technique was employed for counting fleas before each treatment and at the end of the trial period. Efficacy values were calculated by comparing posttreatment geometric mean flea counts with baseline data collected before the first treatment. Spinosadtreated dogs receiving doses below 45 mg/kg or higher than 70 mg/kg were excluded from the dataset for analysis. The proportion of dogs on which no fleas could be found was also recorded.
Results
Flea populations established on dogs one day before treat ment were completely eliminated. Residual efficacies in the three laboratory studies were greater than 99 per cent at three weeks posttreatment, with values of 97.8, 96.5 and 96.5 per cent, respectively, on day 30. In the two field trials, data from 93 and 43 spinosadtreated dogs were compared with data from 93 and 71 selamectintreated dogs, respectively. Group mean flea counts were initially between 29.7 and 40.7 fleas per dog, with individual counts up to 560 fleas. The flea burden of spinosad treated dogs was reduced by 97 per cent 14 days after the first treatment and by 99.6 per cent at days 60 and 90. Corresponding figures for selamectin were significantly lower (P<0.05) at all time points (88.5 to 90.7 per cent at day 14, 97.8 per cent at day 60 and 98.2 per cent at day 90 after treatment). 'Zeroflea' values during the first month varied from 39.5 to 59.1 per cent for spinosadtreated dogs and from 28.6 to 34.1 per cent for selamectintreated dogs; these values increased thereafter and became signifi cantly different (P=0.042) by day 90 at 85.0 per cent and 67.1 per cent, respectively.
Interpretation
The performance of spinosad in field trials can be ascribed to its combined pulicidal attributes. Laboratory studies con firmed a strong initial 'knockdown' effect and persistent activity. A previous study by other workers demonstrated a rapid speed of kill, starting at 30 minutes, with 100 per cent of fleas dead or moribund within four hours. Spinosad thereby destroys newly acquired fleas before they reach maturity, as evidenced by the 99.8 per cent reduction in flea egg output recorded in that study. Thus, monthly treat ments prevent new eggs replenishing the reservoir of fleas developing in the home, leading to a progressive reduction in hostseeking fleas. In the present study, flea burdens on spinosadtreated dogs were reduced by 99.6 per cent within 60 days, and the 'zeroflea' data suggest that infestations had been eliminated from up to 85 per cent of homes by day 90.
Significance of findings
Effective flea control is a threestage process. First, the removal of fleas from an already infested host provides relief from discomfort. Secondly, the animal must be pro tected from reinfestation by hostseeking fleas already in the household environment. Thirdly, the reservoir of off host lifecycle stages must be abolished to provide long term control. In this series of European studies, spinosad given orally at a doserate of 45 to 70 mg/kg fulfilled these criteria.
